<DOC>
	<DOC>NCT02778477</DOC>
	<brief_summary>The current study is the first clinical trial proposed with PF-06423264. It is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) following administration of multiple ascending doses of PF-06423264 to healthy adult subjects with or without oily skin.</brief_summary>
	<brief_title>Topical Multiple Ascending Dose Study for PF-06423264</brief_title>
	<detailed_description />
	<criteria>Healthy males and female of nonchildbearing potential; Body Mass Index 17.535.5 kg/m2; Body weight &gt;50 kg; Evidence of history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergises, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>